Vogenx is preparing to enter the public markets by filing for a Nasdaq listing, with plans to use the proceeds to advance development of its lead SGLT1 inhibitor. The Durham, North Carolina-based biotech has not yet disclosed the number of shares it intends to sell or its expected offering price. However, regulatory filings show that a significant portion of the IPO proceeds will be directed toward advancing its lead candidate, mizagliflozin.
The company obtained worldwide rights to mizagliflozin in 2021 through a licensing agreement with Kissei Pharmaceutical, excluding Japan, Taiwan, and South Korea. The oral therapy targets sodium-glucose cotransporter 1 (SGLT1), a protein in the gastrointestinal tract that transports glucose from food into the bloodstream.
A similar therapeutic approach has already reached the market through Lexicon Pharmaceuticals’ Inpefa (sotagliflozin), which became the first FDA-approved dual SGLT1/SGLT2 inhibitor in 2023. The drug is approved to reduce the risk of heart failure in adults with a history of the condition or those suffering from chronic kidney issues, Type 2 diabetes and additional cardiovascular risk factors.
Vogenx has already completed two Phase 2 clinical studies of mizagliflozin in patients with post-bariatric hypoglycemia (PBH), a serious complication that can develop months or even years after weight-loss surgery and is characterized by dangerously low blood sugar. The studies demonstrated statistically significant reductions in both glucose absorption and insulin secretion, which served as excellent news for the firm.
The IPO proceeds will support the continued development of the therapy for PBH, including a Phase 2b trial that the company expects to begin enrolling patients later this year.
Additional funding will be allocated to expanding development of mizagliflozin in gastroparesis, a chronic disorder in which the stomach empties more slowly than normal. Vogenx plans to launch a Phase 2 study in 2027 and also intends to seek FDA authorization that year to evaluate the therapy in patients with GIP-dependent Cushing’s syndrome, showcasing that it’s prepared to move fast to get the desired results.
Beyond its lead program, the company’s pipeline includes the preclinical candidate VGX-2857, which Vogenx believes could have potential as a weight-maintenance therapy as well as in other metabolic diseases.
The decision to pursue an IPO comes as the company’s cash reserves have fallen sharply – regulatory filings showed Vogenx held just over $250,000 in cash at the end of March.
Founded in 2021 to develop mizagliflozin, Vogenx raised $11 million in a Series A financing round a year later. The company is led by Chief Executive Officer James Green, who headed metabolic disease biotech Avolynt before joining.
The leadership team also includes Chief Medical Officer William Wilkison, whose previous experience includes roles at both Avolynt and GSK.
Vogenx joins a growing group of biotechnology companies pursuing public listings, including Kalohexis, Attovia Therapeutics, Apnimed, and Braveheart Bio. These companies are seeking to capitalize on renewed investor interest in biotech IPOs, following high-profile market debuts by Parabilis Medicines and Kailera Therapeutics earlier this year.
Vogenx has officially filed for an initial public offering (IPO) on the Nasdaq Capital Market as the biotechnology company seeks to raise capital for the continued development of its metabolic drug programs. The proposed offering reflects Vogenx’s strategy to accelerate clinical research, expand its pipeline, and strengthen its position in the competitive biotechnology sector.
Vogenx Takes the Next Step Toward Public Markets
By filing for a Nasdaq Capital Market IPO, Vogenx aims to access additional funding that will support its long-term research and development objectives. Becoming a publicly traded company could also increase Vogenx’s visibility among investors while providing greater financial flexibility for future growth.
The IPO filing represents an important milestone as the company advances innovative therapies targeting metabolic diseases.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
